General
Preferred name
Evenamide
Synonyms
NW-3509 ()
Evenamide hydrochloride ()
Evenamida ()
P&D ID
PD125846
CAS
1092977-06-4
1092977-61-1
Tags
available
drug candidate
Drug indication
Schizophrenia
Drug Status
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Evenamide (NW-3509) is an orally available voltage-gated sodium channel (VGSC) blocker (Ki=0.4 ¦ÌM) for the research of schizophrenia. Evenamide shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness[1][2].
PRICE
90
DESCRIPTION
Evenamide is a selective voltage-gated sodium and/or calcium channel modulator, including subtypes Nav1.3, Nav1.7, and Nav1.8. It may be potentia useful in preventing, alleviating and curing a wide range of pathologies, including neurol., cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases. It has shown efficacy in animal models of psychosis, mania, depression, and aggression. It was under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia. It is in phase II clinical trials.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Evenamide (NW-3509) is a sodium channel blocker. Which shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
9
BOC Sciences Bioactive Compounds
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugMAP
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
12
Molecular Weight
278.2
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
9
Ring Count
1
Aromatic Ring Count
1
cLogP
2.09
TPSA
41.57
Fraction CSP3
0.56
Chiral centers
0.0
Largest ring
6.0
QED
0.7
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Sodium Channel
Member status
member
MOA
Nav1.3 (Brain Type III) Sodium Channel Blockers
Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers
Nav1.8 (SNS/PN3) Sodium Channel Blockers
voltage-gated sodium channel blocker
Pathway
Membrane Transporter/Ion Channel
Solubility
10 mM in DMSO
Source data
